Fendol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fendol

What is Fendol? An Overview

Property Description
Active ingredient Mefenamic Acid
Form Capsules, Tablets, Oral suspension
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use General relief of pain, inflammation, and fever
Origin Synthetic

What Type of Medicine is Fendol (Mefenamic Acid)?

Fendol is a pharmaceutical preparation that contains the active ingredient Mefenamic Acid, classifying it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is a synthetic, single-ingredient medicine administered via the oral route for systemic action. The active compound, Mefenamic Acid, is chemically categorized as an Anthranilic acid derivative, placing it within the fenamate subgroup of NSAIDs. Mefenamic Acid is clinically recognized for its established role in the management of pain and inflammatory conditions, distinguishing it from non-NSAID analgesics. Its official classification groups it under anti-inflammatory and antirheumatic products.


Composition and Available Forms of Fendol

The therapeutic effect of Fendol is derived solely from the Mefenamic Acid active ingredient, making it a single-entity product. Fendol is formulated for oral use and is commonly available in dosage forms including capsules, tablets, or a liquid oral suspension, which often facilitates administration for patient groups such as adolescents. These various forms ensure the medicine is delivered reliably for systemic absorption, allowing the active substance to circulate throughout the body. The formulations contain Mefenamic Acid alongside necessary pharmaceutical excipients, such as fillers or suspending agents, which aid in stability and effective delivery.


General Benefits and Purpose of Fendol

Fendol's general purpose is to provide symptomatic relief by acting as an analgesic (pain reliever), an anti-inflammatory agent (reduces swelling and irritation), and an antipyretic (fever reducer). The core mechanism involves inhibiting the synthesis of prostaglandins, which are compounds that trigger pain, inflammation, and fever at the cellular level. Clinical data supports that Mefenamic Acid is effective in addressing pain and inflammation by inhibiting these key mediators. This established efficacy makes it suitable for neutral use scenarios, such as addressing moderate pain associated with general physical distress. This specific mechanism allows Fendol to broadly address symptoms where pain, inflammation, and fever are present.

Regulatory References

  1. MedlinePlus Mefenamic Acid

What side effects are possible with Fendol?

Possible Side Effects and Safety Information for Fendol

Fendol is a non-steroidal anti-inflammatory drug (NSAID) and its use is associated with a risk of serious adverse reactions primarily affecting the cardiovascular and gastrointestinal systems, as documented by governmental regulatory authorities.


Adverse Reaction Scope

Key Adverse Reactions and Warnings

System-Organ Class Serious Adverse Reactions (Documented in Regulatory Sources)
Cardiovascular Serious cardiovascular thrombotic events (myocardial infarction and stroke), which can be fatal. This risk may increase with dose and duration of use. Onset or worsening of hypertension, congestive heart failure, and edema are also noted risks.
Gastrointestinal Serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and can occur without warning symptoms. The risk may increase with duration of use.
Other Systemic Risks Hepatotoxicity (liver injury, including enzyme elevation), renal toxicity (including renal papillary necrosis), and serious skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, DRESS), and anaphylactic reactions.

Frequency Classification: Common side effects are reported but serious events are often described by their increased risk rather than a specific frequency class (e.g., “very common” or “rare”).

Population-Specific Considerations: Use is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Increased risk of serious GI and CV events is noted for elderly patients, those with a history of GI disease, or those with established cardiovascular disease or risk factors.

Safety-Related Restrictions: Fendol is contraindicated in patients with known hypersensitivity to the drug, or a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use is also to be avoided at or beyond 30 weeks gestation.


Regulatory Safety Summary

Regulatory documentation highlights Fendol’s association with the significant systemic risks inherent to the NSAID class, imposing a Boxed Warning format for the potential for fatal cardiovascular thrombotic events and serious gastrointestinal ulceration/bleeding. The official safety structure emphasizes that patients should use the lowest effective dose for the shortest duration possible to minimize these documented risks.

Overdose and Emergency Response

Overdose and When to Seek Help (Fendol / Mefenamic Acid)

The information in this section strictly reflects official regulatory guidance on Mefenamic Acid overdose and mandated emergency procedures.


Documented Manifestations and Severe Outcomes

Official prescribing information indicates that an overdose may be characterized by nausea, vomiting, and upper abdominal pain. Central nervous system (CNS) effects are common, presenting as lethargy, drowsiness, and the potential for seizures. In severe cases, the progression to coma and the potential for acute renal failure (acute kidney injury) are recognized severe outcomes. Regulatory documents also note the possible occurrence of hypoprothrombinemia and the risk of fatal outcomes.


Mandated Emergency Actions

Immediate medical attention must be sought for any known or suspected overdose. Individuals must contact emergency services without delay, as the situation may be life-threatening. Management is strictly symptomatic and supportive, as no specific antidote is known for Mefenamic Acid. Officially described supportive procedures include the administration of activated charcoal and, in acute cases, gastric lavage may be considered. Hospital monitoring is required for continuous observation, particularly to assess and manage renal function, which is a key area of concern in overdose.

Therapeutic Uses of Fendol

Fendol (Mefenamic Acid) is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. The medication is primarily relevant for easing symptoms related to physical discomfort and addressing inflammatory or irritative states.

Common therapeutic uses include the symptomatic management of mild to moderate acute pain, menstrual pain (primary dysmenorrhea), and symptoms associated with inflammatory conditions like rheumatoid arthritis and osteoarthritis. The medication may also assist with the symptomatic reduction of elevated body temperature, or fever. Fendol is applied across domains where symptoms associated with acute or episodic changes interfere with daily functioning.

It is commonly used when short-term symptomatic assistance is needed for situations like headaches, muscle aches, or post-procedural discomfort. The medication is applied in addressing symptom clusters that may become intense or disruptive. By assisting with the management of these manifestations, Fendol assists with maintaining functional stability when symptoms are more noticeable, supporting patients during difficult symptomatic phases.


Quick Fact: Relief for Episodic Pain
Fendol is considered relevant for easing pain that is recurrent or cyclical, such as the cramping and discomfort experienced during primary dysmenorrhea.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Fendol (Mefenamic Acid) — Official Regulatory Information

Fendol (Mefenamic Acid) eligibility is defined by regulatory authorities based on pre-existing health conditions, age, and reproductive status. The medicine is primarily intended for use by adults and adolescents ge 14 years of age for pain relief. Specific oral suspension formulations may be indicated for fever in children ge 6 months of age in some regions, though its use for pain is not generally established in those under 14 years.

Contraindicated Populations

Fendol is strictly contraindicated for several groups due to serious risk. Individuals with known hypersensitivity to Mefenamic Acid, aspirin, or other NSAIDs must not use the medicine. It is also prohibited for patients with active ulceration or chronic inflammation of the GI tract, severe heart failure, severe renal failure, or severe hepatic failure.

Use Restrictions and Cautions

Pregnancy and Lactation: Use is contraindicated during the third trimester of pregnancy (from 30 weeks' gestation). Use is not recommended while breastfeeding. Older adults must use Fendol with caution due to a heightened risk of serious adverse reactions, especially gastrointestinal bleeding. Conditional use and monitoring are required for patients with uncontrolled hypertension or mild-to-moderate organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Fendol (Mefenamic Acid)

The official interaction profile of Mefenamic Acid is established by government regulatory documents, defining constraints based on pharmacodynamic risks and pharmacokinetic alterations.

Interaction Scope and Restrictions

Category Official Regulatory Statement
Medicinal products with documented interactions Oral Anticoagulants, Anti-platelet Agents, SSRIs, Corticosteroids, Diuretics, ACE Inhibitors, ARBs, Lithium, Methotrexate, and Antacids.
Interaction-related restrictions Co-administration with other systemic non-aspirin NSAIDs is formally prohibited. Use for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery is contraindicated.
Population-specific notes Elderly or volume-depleted patients face a heightened risk of renal dysfunction when co-administered with ACE Inhibitors or ARBs. CYP2C9 poor metabolizers risk abnormally high plasma exposure due to reduced clearance.

Official Interaction Statements

  • The medicine may diminish the antihypertensive effect of ACE Inhibitors and Diuretics, and concurrently increase the risk of renal injury.
  • Co-administration with Oral Anticoagulants (e.g., Warfarin), Corticosteroids, or SSRIs may substantially increase the risk of bleeding complications.
  • Fendol reduces the renal clearance of Lithium, leading to elevated plasma concentrations and potential toxicity.
  • Antacids containing Magnesium Hydroxide are documented to significantly increase the rate and extent of Mefenamic Acid absorption. Concomitant consumption of alcohol also increases the risk of gastrointestinal bleeding.
  • The anti-platelet effect of low-dose aspirin is interfered with when co-administered.

Connection to the overall interaction profile

The regulatory profile strictly defines boundaries where use is prohibited or requires extreme caution. The constraints center on pharmacodynamic interactions that enhance bleeding risk and nephrotoxicity, alongside pharmacokinetic interactions that officially alter systemic exposure for both Fendol and critical co-administered drugs.

Mechanism of Action

️ How Fendol Works: Pharmacodynamics of Mefenamic Acid

The active ingredient, Mefenamic Acid, operates via a dual molecular mechanism that modulates pathways associated with heightened physiological responses. Fendol acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2) at their active sites, preventing the synthesis of inflammatory mediators like PGE2 . Simultaneously, Mefenamic Acid functions as an antagonist by blocking specific Prostaglandin Receptors ( EP receptors) on target cells, thereby modulating signal transduction by preventing prostaglandin ligand binding.

This reduction of prostaglandins alters nociceptive pathway activity through suppression of prostaglandin-mediated sensitization of afferent peripheral nerve endings. Centrally, the mechanism interferes with PGE2-driven elevation of the hypothalamic thermoregulatory set-point in the CNS, resulting in physiological consequences that facilitate the return to thermal equilibrium. However, the non-selective engagement of COX-1 consequently affects pathways reliant on COX-1 derived prostanoids, such as those governing gastric mucosal integrity and regulating renal blood flow.

Dosage and Administration Information

How Fendol (Mefenamic Acid) Is Used

Fendol is administered via the oral route for systemic use, with official usage protocols strictly governed by established guidelines. The medicine is primarily employed for short-term, acute symptom management, and its use is subject to specific timing and duration constraints.


Official Usage Patterns

Usage Entity Official Label-Based Instruction Summary
Route of Administration Oral
Standard Adult Regimen An initial 500 mg dose is taken once, followed by 250 mg maintenance doses at defined intervals.
Dosing Frequency Typically administered every six hours (q6hr) as needed for acute symptoms, or sometimes three times daily in some regions.
Timing with Meals Must be taken with food, milk, or a full glass of water to reduce the potential for gastrointestinal irritation.
Course Duration Use for acute pain must not exceed seven days, and for primary dysmenorrhea, it is generally limited to two to three days.
Dosing Principle The fundamental requirement is to use the lowest effective dose for the shortest possible duration.

Administration Context and Specific Rules

For administration in cases of primary dysmenorrhea, the dosing is initiated at the onset of bleeding and associated pain. Standard instructions emphasize that if a dose is missed, it should be skipped if the next dose is due soon; double doses must not be taken. For older adults, the lowest effective dose for the shortest duration is required due to recognized differences in drug disposition.

Recent Clinical Evidence

Research evidence / Overview of Studies for Fendol

Fendol (Mefenamic Acid) has been evaluated primarily through Randomized Controlled Trials (RCTs) and systematic reviews focusing on acute and episodic symptom management. The research focuses on strictly defined short-term outcomes, with limited data available for long-term use or preventative treatment.


Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in primary dysmenorrhea has primarily involved short-term RCTs conducted over two to three menstrual cycles. Studies reported measurements of pain intensity and duration, alongside the monitoring of additional medication use in adult women and adolescents. Research highlights reported values measured during the study period, although the evidence base for use beyond three consecutive cycles is not fully established.


Evidence for Use in Mild to Moderate Acute Pain

Research involving Fendol was evaluated in contexts involving conditions associated with acute episodes, such as dental pain. These single-dose, short-term RCTs focused on the measurement of pain scores over intervals typically lasting 4 to 8 hours. The data are based on maximum observation periods of one week. The full extent of the evidence base for treatment durations exceeding the recommended seven days for acute pain is not characterized.


Evidence in Special Populations and Inflammatory Studies

Studies in children and adults have been conducted to monitor measurements in body temperature in relation to the medicine's antipyretic function. For chronic inflammatory conditions, such as rheumatoid arthritis, studies monitored outcomes linked to inflammatory states. Non-clinical research has reported observations that the substance was not associated with halting the progression of joint damage. Data for long-term outcomes remain variable, and the evidence is largely restricted to symptomatic patterns.

Key Studies & References

  1. Mefenamic Acid - LiverTox - NCBI Bookshelf (Review of clinical use and properties)
  2. The Antipyretic Effect of High-Dose Paracetamol Versus Mefenamic Acid in the Treatment of Febrile Children: A Randomized Control Trial
  3. Public Assessment Report National Procedure Mefenamic Acid 500 mg film-coated Tablets (Regulatory document on authorized use)

Frequently Asked Questions (FAQ)

Common questions about Fendol (FAQ)

Q: What is the difference between Fendol and [similar common drug name]?

A: Official documents classify the active ingredient in Fendol, Mefenamic Acid, as an Anthranilic acid derivative, placing it in the fenamate subgroup of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

This specific chemical classification defines its structure and pharmacological profile compared to other types of NSAIDs.

Q: Are there any dietary restrictions mentioned in the official instructions for Fendol?

A: Official product information states Fendol should be taken with food, milk, or a full glass of water to help reduce the potential for stomach irritation.

Warnings are issued against consuming alcohol and antacids containing Magnesium Hydroxide due to known interaction risks. No other broad dietary restrictions are explicitly mandated in official regulatory documents.

Q: Can older adults typically use Fendol?

A: Official documentation indicates Fendol can be used by older adults but requires caution due to a heightened risk of serious adverse reactions, particularly gastrointestinal bleeding.

For this population, use is strictly constrained to the lowest effective dose for the shortest possible duration.

Q: How long does it usually take for Fendol to start working?

A: Studies and official information indicate that the effects of Fendol for acute pain are typically monitored over intervals lasting 4 to 8 hours.

Dosing is often scheduled every six hours as needed to maintain symptom management.

Q: What are the most commonly reported side effects in official safety reports for Fendol?

A: Official reports document several common, non-serious side effects that may occur, including stomach discomfort, diarrhea, nausea, vomiting, and dizziness.

Serious adverse events are also described, which are associated with a greater risk when the medicine is used for longer periods of time.

Q: Are there any long-term health concerns associated with Fendol?

A: Regulatory documentation explicitly warns that the risk of serious side effects, such as cardiovascular thrombotic events (heart attack and stroke) and gastrointestinal bleeding, may increase with the duration of use.

Official recommendations consistently emphasize limiting use to the shortest duration possible to minimize these documented risks.

Q: Can Fendol be taken with heart or blood pressure medications?

A: Fendol is known to interact with certain heart and blood pressure medications, including ACE Inhibitors, ARBs, and Diuretics.

The interaction may diminish the effect of the heart medication and concurrently increase the risk of kidney injury.

Q: Can Fendol cause drowsiness?

A: Official safety reports list both dizziness and potential drowsiness as known side effects of Fendol.

Official instructions advise that if a patient experiences these effects, their ability to drive or operate machinery may be impaired.

Q: Is it possible to become dependent on Fendol?

A: Fendol (Mefenamic Acid) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not classified as a controlled substance or a narcotic.

Official regulatory documents do not classify it as having a potential for physical dependence.

Q: Is Fendol considered a controlled substance?

A: Fendol's active ingredient, Mefenamic Acid, is generally not classified as a controlled substance or a scheduled drug by major national drug control authorities.

This means its legal classification is different from opioid pain medications.

Q: Is it normal to feel a bit nauseous when first starting Fendol?

A: Yes, official documents list nausea as a commonly reported side effect, especially when first starting the medicine.

Taking Fendol with food or milk is officially recommended to help reduce the potential for stomach discomfort.

Q: Can Fendol interact with common supplements like vitamins?

A: Official interaction summaries mainly focus on prescription medications, but regulatory instructions advise patients to inform a healthcare provider of all co-administered products.

This includes vitamins, herbal supplements, and over-the-counter products, as unforeseen interactions may still occur.

Q: Is Fendol available over the counter, or is it prescription-only?

A: Fendol (Mefenamic Acid) is generally classified as a prescription-only medicine in major regulatory jurisdictions.

This means a valid prescription from a licensed healthcare provider is required to obtain the medication.

Q: Is Fendol suitable for vegetarians or those with gelatin allergies?

A: The specific formulations of Fendol (tablets, capsules, or suspension) contain inactive ingredients (excipients) necessary for delivery.

These excipients may include common components like lactose, gluten, or gelatin. Official documents advise patients with known allergies or sensitivities to consult the full excipient list.

Q: Is there a generic version of Fendol available?

A: Yes, the active ingredient in Fendol is Mefenamic Acid, which is available as a generic medicine.

Generic versions are typically authorized by regulators and contain the same active ingredient, dose, and form as the brand-name product.

Q: Is Fendol known to cause any changes in mood or sleep?

A: Official safety reports include rare instances of effects on the nervous system and mood, such as insomnia (difficulty sleeping) and nervousness.

Patients experiencing any unusual changes are advised to seek a professional assessment.

Q: Does Fendol work differently for men versus women?

A: Official clinical pharmacology data do not generally indicate significant differences in how Fendol works in the body between men and women.

The exception is its specific approved use for treating primary dysmenorrhea (menstrual pain), a female-only condition.

Q: Is Fendol approved by the FDA (or similar health agency)?

A: Yes, Fendol (Mefenamic Acid) is an approved medicine that has received authorization from major governmental health authorities.

This includes the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: What kind of monitoring might be necessary while taking Fendol?

A: Official documentation recommends that for patients using Fendol for longer than the standard short-term period, the healthcare provider may need to monitor for signs of renal toxicity (kidney injury).

They may also check for indicators of liver function injury through laboratory tests.

Q: How does Fendol affect driving ability?

A: Fendol may cause documented side effects like dizziness, tiredness, or vision disturbances.

Official documentation advises that if a patient experiences any of these effects, their ability to drive or operate machinery may be impaired.

Q: What is the risk of overdose described in Fendol documentation?

A: Official documentation on overdose primarily describes symptoms such as lethargy, drowsiness, confusion, nausea, vomiting, and upper abdominal pain.

Serious symptoms may include convulsions, acute renal failure, or coma, and require emergency medical attention.

Q: If I have a history of seizures, can I still take Fendol?

A: Official documentation includes a warning regarding the use of Fendol in patients with pre-existing conditions that may predispose them to convulsions (seizures).

This is considered an important precaution by regulatory bodies.

Q: What are the signs of a serious side effect from Fendol?

A: Signs of a serious side effect, as described in official guides, include unusual bleeding or bruising, black or bloody stools, or symptoms consistent with heart attack or stroke (e.g., chest pain, weakness on one side of the body).

Signs of an allergic reaction may include swelling of the face or difficulty breathing.

Q: What should I do if I think Fendol is not working for me?

A: Official usage protocols state Fendol is intended for the shortest possible duration, generally not exceeding seven days for acute pain.

If symptoms persist or worsen beyond the maximum recommended treatment duration, official guidelines recommend assessment by a healthcare provider.

How should Fendol be stored and disposed of?

How to Store and Dispose of Fendol (Mefenamic Acid)

Fendol must be stored according to regulatory requirements to maintain its stability and ensure safety. Store the medicine at controlled room temperature, specifically between 20 C and 25 C. It is strictly required that the product not be stored above 30 C and must be protected from moisture; do not keep the container in damp areas like a bathroom. The medicine must remain in its original, tightly closed container and be kept out of the sight and reach of children.

For disposal of unused or expired Fendol, use a community drug take-back program. If a take-back program is unavailable, follow the FDA-approved procedure for household trash disposal by mixing the medicine with an unappealing substance, placing it in a sealed container, and then discarding it in the trash. The medication should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fendol found in:

A-Z Index: